Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
May 2025—This won’t be news to CAP TODAY readers, but it bears saying: Pathology and laboratory medicine are among the most heavily regulated parts of the health care system in the United States. This regulation is so ingrained in our culture as pathologists that we sometimes deal with it without even thinking. It’s part of our training as residents and remains part of our daily work as pathologists for our entire career.
May 2025—Independent risk factors for many cancers include health conditions such as type 2 diabetes and obesity. Glucagon-like peptide-1 receptor agonists (GLA-1RAs) are an effective treatment for these chronic conditions and provide glycemic control, weight reduction, and immunomodulation. In a recent study, GLP-1RAs were associated with lower cancer risk in solid tumor cancers. However, the relationship between GLP-1RAs and hematological cancers has not been explored. Therefore, the authors conducted a study to compare the risk of hematological cancers in patients with type 2 diabetes treated with GLP-1RAs to that of patients with type 2 diabetes treated with metformin or insulin. The primary outcome was a first diagnosis of a hematological cancer within 15 years of an antidiabetic drug being prescribed. The retrospective cohort study used TriNetX, a repository of aggregated electronic health record data of medical encounters for approximately 25 percent of the U.S. population. The platform includes medical information from various age groups, racial and ethnic backgrounds, income levels, and insurance types.
May 2025—Many pancreatic neuroendocrine tumors fall into two major prognostic subtypes based on DAXX/ATRX-induced alternative lengthening of the telomerase phenotype and alpha- and beta-cell-like epigenomic profiles. However, some do not fit into either subtype. Furthermore, despite advanced genotyping, pancreatic neuroendocrine tumors (PanNET) are generally not well characterized in terms of their histologic and hormonal phenotypes. The authors conducted a study to identify new subgroups of PanNET by extending transcription factor signatures and investigating their correlation with histologic, hormonal, molecular, and prognostic findings. One hundred eighty-five PanNET (165 nonfunctioning and 20 functioning), resected between 1996 and 2023, were classified into the subgroups A1, A2, B, C, and D.
May 2025—As genomic technology and scientific knowledge advance, so too do their applications in health care. Clinical genetic testing, preimplantation genetic diagnosis (PGD), and heritable human genome editing (HHGE) are an ever-growing and evolving part of genomic medicine. The author explored the significance of lived experiences with genetic disease relative to understanding the severity or seriousness of such diseases in the genomic age. She focused on severity of disease, perceptions of symptoms of disease or associations with disease, and interplay between symptoms of disease and associations with disease. The data presented were collected as part of a larger mixed-methods research project exploring factors that influence attitudes toward the use of HHGE as a potential reproductive choice in the United Kingdom and how identifying those factors could aid the design of future regulations.
May 2025
Q. Our laboratory is considering adding whole slide imaging to our surgical pathology case workflow. The quality of the slides can have a negative impact on the scanning of the histologic sections. How can our histology laboratory produce histologic preparations that are optimal for whole slide imaging scanning? Read answer.
Q. Are there biological reference intervals for spot urine values for creatinine, protein, microalbumin, sodium, potassium, and calcium? Some reagent manufacturers give reference intervals for spot urine tests. Is this necessary? Read answer.
May 2025—Duke University has launched its Duke Center for Computational and Digital Health Innovation, which is intended to drive technological advances in the areas of wearable sensors, high-performance computing, and extended reality solutions. “Our center provides a vibrant platform for innovation and collaboration, where researchers, clinicians, engineers, and industry partners work side-by-side to pioneer new solutions,” says an open letter from Amanda Randles, PhD, director of the center. Faculty support for the center comes from the Duke University School of Medicine, School of Nursing, Trinity College of Arts and Sciences, and Pratt School of Engineering.
May 2025—Ninety-nine percent of laboratory professionals say medical couriers impact their work in a “typical week,” with 81 percent of respondents who work in acute care labs indicating the impact is “significant,” according to a CAP TODAY survey sponsored by MedSpeed. Of the 318 laboratory professionals who responded to the 2025 CAP TODAY survey, 84 percent said that in the last month a medical courier delay or error impacted their ability to provide appropriate and timely results for patients, with an average of three such incidents reported per month per respondent. Fifty-six percent of laboratory directors, managers, and supervisors indicated that a courier error compromised an irreplaceable specimen in the last year, with an average of two such incidents reported per respondent per year. And 83 percent of laboratory directors, managers, and supervisors said courier reliability affects their decision to partner with specialty labs or complementary labs for send-out and referral testing.
